Serrapeptase
Biochemical Structure and Enzymology
Serrapeptase, officially classified as serratiopeptidase or serralysin, is an extracellular metalloendopeptidase. It is composed of 470 amino acids and has a molecular weight of approximately 50,000 kDa. The enzyme is produced by the Gram-negative bacterium *Serratia marcescens* ATCC 27117 (formerly known as Serratia strain E-15), which was originally isolated in the 1960s from the intestines of the silkworm *Bombyx mori*. In nature, the silkworm utilizes this secreted enzyme to dissolve its tough, fibrous cocoon, allowing the moth to emerge.
The active site of serrapeptase contains a crucial zinc atom, which is essential for its proteolytic activity. As an endopeptidase, it cleaves internal, nonterminal peptide bonds within polypeptide chains rather than cleaving amino acids from the ends (exopeptidase activity). Its maximal proteolytic activity is observed at a physiological temperature of 40°C (104°F) and an alkaline pH of approximately 8.0, though it remains active across a pH range of 6 to 10. The enzyme is highly sensitive to heat; maintaining it at 55°C (131°F) for just 15 minutes results in complete thermal inactivation.
Mechanisms of Action: Mucolytic and Anti-Biofilm Properties
While historically marketed as a systemic anti-inflammatory agent, the most biochemically substantiated mechanisms of serrapeptase revolve around its mucolytic and anti-biofilm capabilities.
1. Mucolytic Action: Serrapeptase alters the rheological properties of respiratory tract secretions. By hydrolyzing specific structural proteins within mucus, it reduces the viscoelasticity of sputum. This thinning of mucus facilitates easier expectoration and enhances mucociliary clearance, which is particularly relevant in conditions characterized by hypersecretion of thick mucus, such as chronic bronchitis, asthma, and cystic fibrosis.
2. Biofilm Disruption: Bacterial biofilms are complex, extracellular polymeric matrices that protect bacterial colonies from host immune responses and antimicrobial agents. Serrapeptase has been shown to modify bacterial surface adhesins, effectively preventing bacteria from adhering to host tissues or medical devices. By degrading the proteinaceous components of the biofilm matrix, serrapeptase not only disrupts existing biofilms but also increases the susceptibility of the bacteria to endogenous immune cells and exogenous antibiotics.
3. Fibrinolytic and Caseinolytic Activity: In vitro, serrapeptase demonstrates the ability to degrade fibrin and casein. This has led to hypotheses regarding its potential to dissolve blood clots and atherosclerotic plaques. However, the translation of these in vitro fibrinolytic properties to in vivo systemic effects in humans remains highly controversial and poorly supported by rigorous clinical data.
Pharmacokinetics and the Bioavailability Hurdle
The most significant limitation of serrapeptase as an oral therapeutic agent is its pharmacokinetics. As a large, 50 kDa protein, serrapeptase is highly susceptible to proteolytic degradation by pepsin in the acidic environment of the stomach. Consequently, oral formulations must be enteric-coated to survive gastric transit.
Even with enteric coating, the intestinal absorption of intact serrapeptase is exceedingly low. The intestinal epithelium is designed to absorb single amino acids and small di- or tri-peptides, not massive 50 kDa macromolecules. While trace amounts of the enzyme have been detected in systemic circulation and plasma following oral administration—suggesting some degree of paracellular transport or specialized transcytosis—the overall bioavailability is considered unreliable and sub-therapeutic for systemic anti-inflammatory purposes. This pharmacokinetic reality aligns with the findings of recent clinical reviews, which note that oral serrapeptase is generally ineffective for distant joint health or systemic inflammation.
What drugs interact with serratiopeptidase? +
What not to take with serrapeptase? +
What are the common side effects of serratiopeptidase? +
How often should you take peptidase tablets? +
Is serrapeptase effective for joint pain? +
How does serrapeptase help with mucus? +
What is the recommended dosage for adults? +
What are the signs serrapeptase is working? +
Can serrapeptase dissolve scar tissue? +
Does serrapeptase cause liver or kidney damage? +
Why must serrapeptase be enteric-coated? +
What is a SPU or SU on a supplement label? +
Can pregnant women take serrapeptase? +
Does serrapeptase clear clogged arteries? +
How long does it take for serrapeptase to work? +
Is serrapeptase vegan? +
Everything About Serrapeptase Article
The Complete Guide to Serrapeptase
Serrapeptase, also known as serratiopeptidase, is one of the most heavily debated supplements in the natural health and sports nutrition spheres. Marketed widely as a systemic enzyme capable of dissolving scar tissue, clearing arterial plaque, and soothing joint pain, the actual clinical evidence paints a much more nuanced—and often contradictory—picture.
What is Serrapeptase?
Serrapeptase is an extracellular proteolytic enzyme (a protein-digesting enzyme) produced by the bacterium Serratia marcescens. Interestingly, this bacterium was originally discovered in the intestines of the silkworm (Bombyx mori). In nature, the silkworm uses this enzyme to dissolve its tough, fibrous cocoon so it can emerge as a moth.
Because of its ability to break down non-living tissue and proteins, researchers in the 1960s began investigating whether it could be used therapeutically in humans to break down inflammatory proteins, mucus, and blood clots.
The Rise and Fall of Serrapeptase in Medicine
In 1968, serrapeptase was introduced to the Japanese pharmaceutical market as a prescription drug. For decades, it was prescribed across various medical specialties—including orthopedics, dentistry, and otolaryngology—for its purported anti-inflammatory, anti-edemic (anti-swelling), and analgesic effects.
However, the medical consensus shifted dramatically in the 21st century. In 2011, Takeda Pharmaceuticals, the primary manufacturer of prescription serrapeptase in Japan, voluntarily recalled the drug from the market. This decision came after post-marketing, double-blind clinical trials revealed that the enzyme was no more effective than a placebo for reducing inflammation.
Following this, a comprehensive 2013 systematic review published in the International Journal of Surgery analyzed 24 clinical studies on serrapeptase. The researchers concluded that the evidence supporting its use as an anti-inflammatory and analgesic agent was based on studies with poor methodology, small sample sizes, and unclear outcomes.
The Bioavailability Problem
Why did a drug that seemed so promising in test tubes fail in human trials? The answer lies in pharmacokinetics.
Serrapeptase is a massive molecule, weighing in at approximately 50,000 Daltons. When you swallow a serrapeptase capsule, it enters the highly acidic environment of the stomach, where digestive enzymes like pepsin quickly denature and destroy it. To combat this, supplement manufacturers use enteric coatings to protect the enzyme until it reaches the alkaline environment of the intestines.
However, even if the enzyme reaches the intestines intact, the human gut is not designed to absorb 50 kDa proteins. The intestinal lining absorbs single amino acids and tiny peptides. While trace amounts of serrapeptase have been detected in the bloodstream in some studies, the overall absorption rate is incredibly low. Examine.com notes that oral absorption through the intestines is so poor that it makes the supplement highly unreliable for systemic issues like joint pain or cardiovascular disease.
What Serrapeptase is Actually Good For
Despite its failure as a systemic anti-inflammatory, serrapeptase is not entirely useless. Current research suggests it has two primary, evidence-backed applications:
1. Mucus Liquefaction Serrapeptase has a well-documented ability to alter the viscoelasticity of mucus. In simpler terms, it thins out thick, sticky phlegm. This makes it easier for the body to clear mucus from the airways. Studies have shown moderate improvements in mucus clearance for patients with chronic airway diseases, such as chronic bronchitis and cystic fibrosis.
2. Biofilm Disruption Bacteria often protect themselves by secreting a sticky, polymeric matrix called a biofilm. This biofilm allows bacteria to adhere to surfaces (like sinus cavities or medical implants) and shields them from antibiotics and the immune system. Serrapeptase has been shown to degrade these biofilms, preventing bacterial adhesion and potentially making antibiotics more effective.
Dosage and Administration
If you choose to use serrapeptase for its mucolytic properties, proper dosing is critical.
Standard Dose: The most commonly studied dose is 10 mg taken three times a day, for a total of 30 mg daily. Enzymatic Units: Supplements often list doses in Serratiopeptidase Units (SPU or SU) rather than milligrams. Approximately 2,000 to 2,600 units are equivalent to 1 mg of serrapeptase. Therefore, a 10 mg dose is roughly equal to 20,000 SPU. Timing: Serrapeptase must be taken on an empty stomach—either 30 minutes before a meal or two hours after a meal. Taking it with food will cause the enzyme to digest the proteins in your meal rather than acting therapeutically. Formulation: Only purchase enteric-coated serrapeptase. Without this coating, the enzyme will be destroyed by stomach acid.
Safety and Side Effects
Serrapeptase is generally well-tolerated in short-term studies (up to 4 weeks). However, long-term safety data is lacking.
Common side effects include mild gastrointestinal upset, nausea, and skin rashes. While rare, serious adverse effects have been reported in the medical literature, including eosinophilic pneumonitis (lung inflammation), bullous pemphigoid (a skin blistering condition), and hemorrhage in patients with Behçet disease.
Because serrapeptase has mild fibrinolytic (clot-dissolving) properties in vitro, it theoretically could interact with blood-thinning medications (anticoagulants or antiplatelets), increasing the risk of bleeding. It is contraindicated for pregnant and nursing women due to a complete lack of safety data in these populations.
The Bottom Line
Serrapeptase is a fascinating enzyme with a complex history. While it is heavily marketed as a miracle cure for joint pain, scar tissue, and inflammation, the clinical evidence does not support these claims, largely due to its poor oral bioavailability. However, if you are struggling with thick mucus, chronic sinus congestion, or biofilm-related issues, an enteric-coated serrapeptase supplement may offer some relief when taken correctly on an empty stomach.